---

• n  anemia characterized by pancytopenia resulting from failure of the bone marrow; can be caused by neoplasm or by toxic exposure

• aplastic anemia

News & Articles

---

• Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic ...
  SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta® (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an ...
  Feb. 28, 2014 - Business Wire